Q3:15 Health Care M&A, by Spending

by | Oct 19, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Last week we shared our data on health care M&A by sector in the third quarter of 2015. Here’s a look at the same sectors, by share of the dollars spent. If you’ve been following health care M&A at all, you won’t be surprised that the Managed Care sector (health insurers) accounts for about 50% of the $198 billion spent. That total, by the way, is also a new quarterly record. Look for The Health Care M&A Report, Third Quarter, for more in-depth analysis by sector. Read More »

Q3:15 Health Care M&A, By Sector

by | Oct 12, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Rehabilitation

Health care M&A in the third quarter was quite robust, with 385 transations reported across 13 sectors. That’s a new record for any third quarter, by the way. We’ll have the full break-out in The Health Care M&A Report, Third Quarter 2015, due to be published by the end of this month. In the meantime, here’s how the sectors fared in Q3:15. Read More »

Personalized Medicine Isn’t All Biotech

by | Sep 14, 2015 8:59 am | Biotechnology, Other Services, Specialty Pharmacies

There are many sides to personalized medicine, and genetic testing is just one. Another cropped up last week in an acquisition made by Restore Health, a privately held Wisconsin company that provides personalized medicines to health care providers across the United States. Its target was Diplomat Pharmacy’s (NYSE: DPLO) compounding pharmacy business, which includes preparation of personalized medicines for patients, and compounding pharmacists who work with prescribers to customize medication to meet specific patient health needs. The deal frees up Diplomat to focus on its core specialty pharmacy operations, which were bolstered with its acquisition of Burman’s Specialty Pharmacy for $82.8... Read More »

The Gores Group Exits with $1.325 Billion

by | Aug 17, 2015 4:11 pm | Biotechnology, Private Equity

Last week’s Biggest Deal was Mallinckrodt plc’s (NYSE: MNK) $1.325 billion acquisition of Therakos, Inc., an immunotherapy company, from The Gores Group. Gores acquired Therakos back in October 2012 for an undisclosed price from Ortho-Clinical Diagnostics. The transaction is expected to be accretive by no less than $0.10 per share to Mallinckrodt’s adjusted diluted fiscal 2016 earnings and increasingly accretive thereafter. With roughly 60% of Therakos’ revenue in the U.S., it expects fiscal 2015 net sales of $185 to $195 million, and anticipates high single-digit growth off that base going forward. Read More »

Deal Volume Rose in July

by | Aug 10, 2015 8:52 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

July’s combined transaction total hit 127 deals, up 2% compared with the bang-up month of July 2014, which had 124 transactions. The Services sector had a strong performance, accounting for 60% of deal volume. Long-Term Care made up 27% of the volume overall with 34 announced transactions. That equalled the record set last July for the sector, and will probably break it as more deals come to light. The Managed Care sector posted some extra activity, although seven deals versus two deals the month prior and a year ago isn’t moving  the needle very high. July 2015 DealsShare of Total Services Behavioral Health Care32% Home Health & Hospice23% Hospitals76% Labs, MRI & Dialysis43%... Read More »

Celgene Continues Its Buying Spree

by | Jul 20, 2015 3:37 pm | Biotechnology

Celgene Corporation (NASDAQ: CELG) made yet another major acquisition last week, picking up Receptos, Inc. (NASDAQ: RCPT) for $7.2 billion. The acquisition significantly boosts Celgene’s Inflammation and Immunology portfolio with the addition of Receptos’ lead product candidate, Ozanimod, which is in Phase 3 tests to treat immune-inflammatory indications in irritable bowel syndrome and relapsing multiple sclerosis. This is Celgene’s biggest deal in 2015, out of the six it has announced. So far, the drug maker has splurged nearly $8.8 billion on acquisitions, collaborations with other drug makers and licensing deals. Read More »